Clinical Trial Update: Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 clinical trial evaluating RGH-188 for schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• RGH-188

Snippet

Sponsor: Forest Laboratories | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED